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Abstract
Background: VHR is a dual-specificity phosphatase, which
dephosphorylates activated ERK1/2 and weakens the ERK
signaling cascade in mammalian cells. A selective inhibitor is
expected to be useful for revealing the physiological function of
VHR.
Results : First, we investigated the molecular mechanism of
VHR inhibition by a known natural product, RK-682. Kinetic
analysis indicated that inhibition was competitive toward the
substrate, and two molecules of RK-682 were required to inhibit
one molecule of VHR. Based on the structure^activity relation-
ships for VHR inhibition by RK-682 derivatives, we constructed a
binding model using molecular dynamics calculation. Based on
this model, we designed and synthesized a novel dimeric
derivative. As expected, the dimeric derivative showed increased
inhibition of VHR, supporting our proposed mechanism of VHR
inhibition by RK-682.
Conclusion: We have developed a novel inhibitor of VHR based
on the results of kinetic analysis and docking simulation. ß 2001
Elsevier Science Ltd. All rights reserved.
Keywords: Dual-speci¢city protein phosphatase; Protein phos-
phatase inhibitor; RK-682; VHR
1. Introduction
Protein phosphorylation plays critical roles in the con-
trol of various cellular functions, such as cell growth, pro-
liferation, oncogenic transformation, and cell cycle pro-
gression. The balance of tyrosine phosphorylation is a
result of interplay between protein tyrosine phosphatases
(PTPs) and protein tyrosine kinases. Perturbation of this
balance is thought to be involved in the pathogenesis of
cancer and other diseases.
Dual-speci¢city PTPs (DS-PTPs) are members of a large
family of enzymes that catalyze the hydrolysis of phospho-
monoester bonds in protein substrates. The DS-PTPs act
e⁄ciently on phosphotyrosine as well as phosphothreo-
nine/serine residues [1^3]. Approximately 20 distinct DS-
PTPs have been identi¢ed to date. The gene of the ¢rst
identi¢ed human DS-PTP, named VHR (vaccinia VH1-
related phosphatase), was isolated by an expression clon-
ing strategy and has been the subject of detailed biochem-
ical and structural analyses [4]. DS-PTPs and PTPs share
the active site motif (His/Val)Cys(X)5Arg(Ser/Thr), but
display little amino acid sequence identity outside of the
active site. Reported crystal structures of PTPs and DS-
PTPs, including VHR [5], indicate that this motif forms a
loop structure, which is thought to interact directly with
the phosphate residue of the substrate through multiple
hydrogen bondings between amide NH and phosphate
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oxygen atoms. VHR was recently reported to act as a
physiological regulator of ERKs, extracellular regulated
kinases, which are members of the MAP (mitogen-acti-
vated protein) kinase family [6]. VHR is a constitutively
expressed tyrosine-speci¢c ERK phosphatase, localized to
the nucleus, and is responsible both for the rapid inacti-
vation of ERK after its activation and for its repression in
quiescent cells. Speci¢c inhibitors of VHR are expected be
useful for revealing the physiological functions of VHR
and also ERK signaling, but only a few VHR inhibitors
have been reported so far [7^11]. Since most of them also
inhibit other enzymes [7^14], a more selective inhibitor of
VHR is required.
To develop a powerful and selective inhibitor of VHR,
we focused on a tetronic acid derivative, RK-682 (1, see
Fig. 1), which had been isolated from Streptomyces sp. 88-
682 by our group [7] (in this paper we preliminarily re-
ported that 1 was a non-competitive-type inhibitor of
VHR, but the experiments described here clearly show
that 1 is in fact a competitive inhibitor). We have already
synthesized many RK-682 derivatives and clari¢ed the ba-
sic structure^activity relationships (SAR) [15^17]. The
SAR suggest that highly acidic 3-acyltetronic acid repre-
sents a ‘core’ structure that directly interacts with the ac-
tive site loop as a phosphate mimic. However, kinetic
analysis suggested that the mode of inhibition of VHR
by 1 involved two molecules of 1. In this paper we present
details of the kinetic analysis, and we describe the con-
struction of a VHR-RK-682 binding model, and the devel-
opment of a novel VHR inhibitor based on the binding
model.
2. Results and discussion
2.1. Kinetic analysis of VHR inhibition
We evaluated the ability of RK-682 (1) to inhibit VHR
phosphatase activity, and investigated the mode of inhibi-
tion of VHR by 1. We analyzed the inhibition kinetics of 1
and arsenate, a known competitive PTP inhibitor, on
VHR-catalyzed hydrolysis of p-nitrophenyl phosphate
(pNPP). In each case, a characteristic intersecting line
pattern indicating competitive inhibition was observed
(Fig. 2A,B). However, the second-order plots showed dif-
ferent patterns (Fig. 2C,D). That for arsenate (Fig. 2D)
showed a linear relationship, and the inhibition constant
(Ki value) was determined to be 21 WM. In contrast, a
quadratic-like curve was observed in the second-order
plot for 1 (Fig. 2C). This indicated that two molecules
of 1 might bind to and inhibit VHR. Indeed, changing
the horizontal axis from [1] to [1]2 resulted in a good linear
plot (Fig. 2C, inset). The slight deviation from the line at
low [1]2 might suggest the sequential binding of two mol-
ecules of 1 to VHR (see Section 4).
2.2. SARs of RK-682 derivatives
We previously reported the SARs of RK-682 derivatives
as inhibitors of VHR, and showed that a free acidic te-
tronic acid group and a long acyl chain at the C-3 position
of 1 are important for the inhibitory activity [17]. These
results suggested that both ionic interaction through the
dissociated tetronic acid moiety and hydrophobic interac-
tion through the long alkyl chain are important for VHR
inhibition. The C-3 ester derivative 2 inhibited VHR with
a similar value of IC50 (14.5 WM) to that of 1 (11.6 WM),
whereas derivatives with a shorter hydrophobic chain
showed weaker or no inhibition (3 : IC50 120 WM, 4 :
IC50s 250 WM). But the 5-decanoyl derivative of 4 (5)
did inhibit VHR with a comparable value of IC50 (37.2
WM) to that of the 5-decanoyl derivative of 1 (6 : 37.9 WM).
These facts indicate that a long hydrophobic acyl chain at
the C-5 position can compensate for a shorter acyl chain
at the C-3 position. Since the kinetic analysis suggested
that two molecules of 1 are involved, we prepared the
simple RK-682 dimer 7, in which the tetronic acid heads
are connected by a C22 methylene linker (see Fig. 3). The
inhibition pro¢les of these compounds are compared in
Fig. 4A. Although the IC50 value (ca. 12 WM) of 7 was
similar to that of 1, the slope of the residual activity curve
was very di¡erent, suggesting that compound 7 inhibits
VHR in a di¡erent manner. Indeed, the second-order
plot (Fig. 4B) indicated that 7 binds to and inhibits
VHR with 1:1 binding stoichiometry. This fact suggests
that the second tetronic acid group of 7 might occupy the
position of the second RK-682 molecule. Similar slopes to
that of 7 were observed for 5 and 6. These results suggest
that compounds 5 and 6 also bind VHR with 1:1 stoichi-
ometry, and the hydrophobic acyl chain at the C-5 posi-
tion may occupy the site at which the C-3 acyl chain of the
second RK-682 molecule binds. It seems probable that the
two hydrophobic acyl chains at the C-5 and C-3 positions
sit in parallel in the hydrophobic groove near the active
site. If this is the case, the methylene linker of the dimer 7
should be tightly folded to ¢t in the groove, and such
conformational restriction may be energetically unfavora-
ble enough to cancel out the favorable interaction between
the second tetronic acid group and the enzyme.
Fig. 1. Structure of RK-682.
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2.3. RK-682 binding model for VHR
Based on the ¢ndings described above and a reported
crystal structure of VHR [5], we constructed a binding
model. The hypotheses we used for model building are
as follows. (1) The tetronic acid anion of the ¢rst molecule
binds to the active site loop (Cys124^Arg130) of VHR.
The competitive inhibition mode of 1 with respect to the
substrate pNPP observed in the kinetic studies and the
importance of the acidic free tetronic acid moiety support
the idea of a direct interaction between the tetronic acid
anion and the catalytic loop structure [17]. (2) The long
alkyl chains of the ¢rst and second molecules have a hy-
drophobic interaction with each other and lie in the hydro-
phobic groove near the active site loop. The SAR and the
single-molecule binding mode of the molecules 5 and 6
with a long hydrophobic acyl chain are consistent with
this hypothesis. (3) The tetronic acid group of the second
molecule has a positive interaction with the basic Arg158
residue of VHR. The guanidino group of Arg158 is lo-
cated at the bottom of the pocket near the active site
loop, and seems to be a good candidate for the putative
binding site for the second tetronic acid group. First, the
sulfate anion bound to the active site loop in the crystal
structure was removed, and the deprotonated RK-682
molecule was manually docked to the active site according
to the hypotheses described above. Next, the second RK-
682 anion was docked into the Arg158 pocket, and the
hydrophobic chains were oriented to the hydrophobic
groove. After preliminary optimization using molecular
mechanics calculations, energy minimization and analysis
of the molecular dynamics in water were carried out using
the Amber 4.1 computer package. Based on the ¢nal en-
ergy-minimized structure, we propose the binding model
shown in Fig. 5.
This model contains many positive interactions. The
¢rst tetronic acid anion is bound to the active site loop
via ionic interaction and/or hydrogen bondings with the
Arg130 side chain and the backbone amide NH (Glu126).
The second tetronic acid anion interacts with the Arg158
Fig. 2. E¡ects of compound 1 and arsenate on VHR-catalyzed hydrolysis of pNPP. (A) Lineweaver^Burk plot of the e¡ect of compound 1 on VHR
activity. Concentrations of 1 were 0 (a), 15 (R), 20 (7), and 25 (F) WM, respectively. (B) Lineweaver^Burk plot of the e¡ect of arsenate on VHR ac-
tivity. Concentrations of arsenate were 0 (a), 0.25 (R), 0.5 (7), and 1 (F) mM, respectively. (C) Second-order plot of (A). The inset shows the second-
order plot of (A) with [1]2 as the horizontal axis. (D) Second-order plot of (B).
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side chain, and hydrogen bonds between the carbonyl oxy-
gen at C-3 position of 1 and amide NH of the active site
loop (Gly127 and Tyr128) are also observed. Signi¢cant
hydrophobic interaction between the two long alkyl chains
of the ¢rst and second molecules and also between the
second chain and hydrophobic amino acid residues of
VHR, such as Leu25, are observed.
The interaction between the alkyl chains would be fa-
vorable for stable binding to VHR because the hydropho-
bic groove is too wide for a single alkyl chain.
2.4. Design and synthesis of a dimeric VHR inhibitor
To con¢rm this binding model, and to develop a more
potent and selective inhibitor of VHR, we designed a nov-
el dimeric compound 8, in which the hydroxymethyl group
of the ¢rst molecule is connected to the side chain of the
second molecule through the appropriate linker (Fig. 5).
The dimeric molecule 8 was expected to exist in the ap-
propriate conformation owing to intramolecular hydro-
phobic interaction, and so should ¢t in the catalytic
groove without signi¢cant conformational change upon
binding.
Synthesis of 8 is shown in Scheme 1. The linker part
having (S)-stereochemistry was synthesized from the L-ke-
toester 9. Asymmetric hydrogenation using Noyori’s cata-
lyst [18] proceeded smoothly to give the desired (S)-10 of
97% ee in 96% yield. Introduction of the hydroxyethyl
group was accomplished via successive allylation, ozonol-
ysis and reduction. Following hydrolysis of the ester
group, silylation, and selective removal of the silyl ester
a¡orded 11. After conversion to the acid chloride, the
carboxylic acid 11 was then condensed with 1 to give 12
in good yield. The resulting 12 was converted to the alco-
hol 13, and the coupling reaction with 14 was achieved in
the presence of silver salt. The optically active thioester 14
was prepared according to the procedure reported before
[15,16]. The desired product 15 and the detritylated prod-
uct 16 were obtained in good combined yield. Each com-
pound was treated with tetra-n-butylammonium £uoride
(TBAF) to construct the tetronic acid moiety, and in the
case of 15, further with hydrochloric acid to a¡ord the
desired compound 8.
2.5. Increased inhibition of VHR by the dimeric molecule 8
As expected, compound 8 showed much more potent
inhibition of VHR than 1 (Fig. 6A; IC50 value of 8 was
1.83 WM), and it showed a competitive/non-competitive
mixed-type inhibition pattern (Fig. 6B). The second-order
plot showed a linear relationship, not a quadratic-like
curve (Fig. 6C), indicating involvement of a single mole-
cule in the inhibition. The synthetic intermediates 13 and
15 without the second tetronic acid group were also tested.
The IC50 values of 13 and 15 were 10.7 WM and 12.3 WM,
respectively, which are similar to that of 1, but much larg-
er than that of 8. Since the slope of the residual activity
curve of 13 was similar to that of 8 (Fig. 6A), the binding
mode of 13 should be similar to that of 8, i.e., single-
molecule binding. These facts are consistent with the pro-
posed critical contribution of the interaction between
Arg158 of VHR and tetronic acid anion to strong binding.
The corresponding Arg residue is conserved in many
Fig. 4. Inhibition of VHR by tetronic acid derivatives. (A) Concentra-
tion-dependent inhibition of VHR by compounds 1, 2, 3, 5, 6, and 7.
(B) Second-order plot for 7.
Fig. 3. Structures of compounds 2^7.
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PTPs, but its environment is di¡erent for each enzyme.
For example, the corresponding Arg440 in Yersinia PTP
and Arg257 in PTP1B are buried and no similar charged
pocket is observed. In some PTPs there is no correspond-
ing Arg residue (for example, Cdc25A). Recently, Puius et
al. reported that PTP1B possesses a non-catalytic aryl
phosphate binding site adjacent to its active site, where
bis-(p-phosphophenyl)methane (BPPM) binds [19,20]. In
the reported crystal structure, the aryl phosphate moiety
of BPPM interacts with Arg24 and Arg254, both of which
are di¡erent from the Arg257 corresponding to Arg158 of
VHR. These features suggested the possibility that com-
pound 8 would discriminate VHR from other PTPs. To
test this possibility, we preliminarily examined the inhib-
itory activity of 8 for PTP-S2 [21], though the environment
of the corresponding Arg residue of this enzyme is still
unknown. As expected, 8 did not inhibit PTP-S2 at
concentrations up to 100 WM. Since there are many PTP
family enzymes, many more PTPs should be tested to
evaluate fully the selectivity of 8. Nevertheless, it is clear
that 8 has at least some selectivity to VHR, and suggests a
guiding principle for designing selective inhibitors of
VHR.
In addition to the previously described SAR data for
compounds 2^7, all of these results obtained with the de-
signed molecule 8 strongly support our model for the
VHR-(RK-682)2 complex.
3. Signi¢cance
We clari¢ed the molecular mechanism of VHR inhibi-
tion by RK-682 using kinetic analysis and SAR data of
RK-682 derivatives. We constructed a model of the VHR-
(RK-682)2 complex with the aid of molecular dynamics
calculations. A novel dimeric molecule 8 was designed
based on the model, and synthesized. The designed mole-
cule 8 showed highly potent inhibition of VHR, as ex-
pected, supporting the validity of our model.
Without the crystal structure of the enzyme^inhibitor
complex, it is not easy to know how the compound inhib-
its the enzyme. Approaches such as kinetic analysis, mo-
Fig. 5. Proposed binding model of VHR-(RK-682)2 complex and design of a dimeric molecule 8 based on this model.
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lecular modeling, and SAR studies have all been used, but
a single approach is rarely e¡ective. The example de-
scribed in this manuscript indicates that the combination
of kinetic analysis, molecular modeling and design, and
synthesis of a designed molecule, is a powerful approach
for solving this problem. Once a reasonable model is in
hand, it should suggest ways to design better inhibitors. In
the case of VHR, our model suggests a critical role of the
Arg158 pocket for strong binding and subtype selectivity.
This ¢nding should be useful for the development of more
powerful and selective VHR inhibitors. Studies along this
line are under way.
4. Materials and methods
4.1. Overexpression and puri¢cation of VHR
The coding sequence for VHR was ampli¢ed using PCR from a
GST (glutathione S-transferase)^VHR fusion gene [4]. The 5P
PCR primer contained an adapter sequence for the DNA restric-
tion enzyme NdeI, and the 3P primer contained a BamHI site
downstream of the native stop codon. The PCR product was
cloned in the pET3a plasmid (Stratagene) to create pET3a-
VHR. The plasmid pET3a-VHR was used to transform compe-
tent Escherichia coli BL21 (DE3) cells. A transformant harboring
this plasmid was grown in 1 l of LB medium containing ampi-
cillin. When the optical density at 600 nm of the culture reached
0.8, IPTG (isopropyl-L-D-thiogalactopyranoside) was added at
1 mM, and incubation of the culture was continued for an addi-
tional 8 h. Puri¢cation of the overexpressed VHR was performed
as previously described [22] with some modi¢cations. The cells
were harvested by centrifugation at 5000Ug, and resuspended in
15 ml of 50 mM Tris (pH 7.4), 1 mM EDTA (ethylenediamine-
N,N,NP,NP-tetraacetic acid), 1 mM DTT (dithiothreitol), 1%
Nonidet P-40, 1 mM PMSF, and lysed by sonication (10 sU6,
at output 8, UR-200P, Tomy Seiko Co. Ltd., Tokyo, Japan). The
cell debris was removed by centrifugation at 17 000Ug for 10
min. Ammonium sulfate was added to the cleared cell lysate at
35% saturation and the solution was stirred for 15 min. There-
after, the precipitate was removed by centrifugation at 17 000Ug,
20 min, ammonium sulfate was added to the supernatant to 65%
saturation, and the solution was stirred, and centrifuged. The
resulting pellet was dissolved in a minimum volume of bu¡er
consisting of 50 mM Tris (pH 7.4), 1 mM EDTA, 1 mM DTT,
1 M NaCl, and loaded onto a Sephadex G-75 gel ¢ltration col-
umn (Amersham Pharmacia Biotech). After elution with the same
bu¡er, the fractions exhibiting phosphatase activity with pNPP as
the substrates were pooled and dialyzed against 500 ml of MES
bu¡er consisting of 20 mM MES (2-(N-morpholino)ethanesul-
fonic acid) (pH 6.0), 1 mM EDTA, 1 mM DTT for 120 min,
three times. The dialysate was loaded onto a POROS SP cation-
exchange column (4.6U100 mm; Perseptive Biosystems) pre-
equilibrated with MES bu¡er. The column was then washed
with MES bu¡er, and the enzyme was eluted with a 0^250 mM
linear NaCl gradient. Fractions containing high phosphatase ac-
tivity with pNPP as the substrate were analyzed by SDS^PAGE
to assess the purity of the enzyme. All fractions which contained
only a single band corresponding to VHR were pooled and con-
centrated by ¢ltration to a ¢nal concentration of 0.2 mM. The
enzyme was stored at 380‡C in 50 mM Tris (pH 7.4), 1 mM
EDTA, until use.
4.2. Phosphatase assays
All enzyme assays were performed using pNPP as the substrate
at 37‡C in 50 mM succinate, 1 mM EDTA, 150 mM NaCl, pH
Scheme 1. Synthesis of 8. (a) Cat. [RuCl2((S)-binap)]2bNEt3, HCl, H2 (5 atm), MeOH, 60‡C, 96% (97% ee); (b) cat. dppb-Pd2(dba)3bCHCl3,
CH2 = CHCH2OCOOEt, THF, 65‡C, 66%; (c) O3, MeOH, 360‡C, then NaBH4, MeOH, 93%; (d) 1 N NaOH, MeOH, room temperature (rt), 98%;
(e) TBDPSCl, imidazole, DMF, rt, 92%; (f) THF^MeOH^H2O, K2CO3, rt, 93%; (g) (COCl)2, DMF, CH2Cl2, rt, then 1, pyridine, CH2Cl2, rt, 89%;
h) TBAF, THF, 73%; (i) 14, CF3COOAg, Na2HPO4, benzene, re£ux, 60% (15)+V40% (16) ; (j) TBAF, THF, 69% (from 16); k) 1 N HCl, MeOH,
60% (from 15, two steps).
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6.0. Immediately after mixing the VHR and pNPP, the reaction
mixture (200 Wl) was incubated at 37‡C for 3 min, then the phos-
phatase reaction was terminated by adding 1 ml of 1 N NaOH.
Phosphatase activity was measured by monitoring the change in
absorbance at 405 nm. PTP-S2 assays were carried out according
to the reported procedure [23].
For steady-state kinetic analysis, phosphatase activity was mea-
sured under conditions in which the pNPP concentration was
varied at ¢xed concentrations of arsenate (Na2HAsO4) and com-
pounds 1^8.
The data obtained were ¢tted to Eq. 1, the Lineweaver^Burk
double-reciprocal form based on the Michaelis^Menten equation:
1=v  1 Km=S=Vmax 1
The second-order plot is based on Eq. 2, where Km app, the
apparent Km value, represents the Km value when 1/v = 0.
Km app  Km 1 I=K i 2
When binding of two inhibitor molecules is required for inhi-
bition to occur, Eqs. 3 and 4 containing the parameter [I]2 can be
derived from Eq. 2. In the case of sequential binding of inhibitor
molecules to the enzyme, Eq. 3 is applicable, and when the two
inhibitor molecules form a dimer before binding to the enzyme,
Eq. 4 is applicable. Ki1 and Ki2 represent the ¢rst and second
inhibitor binding constants, respectively. Kid and Kib represent
the dimerization constant and the enzyme binding constant, re-
spectively.
Km app  Km 1 I2=K i1K i2  I=K i1 3
Km app  Km 1 I2=K ibK id 4
4.3. General methods for the synthesis
Infrared (IR) spectra were measured on an FT/IR-5300 spec-
trometer. 1H- and 13C-NMR spectra were recorded with a Bruck-
er AM-400, AC-200P, or AVANCE 500 NMR spectrometer with
tetramethylsilane used as an internal standard. Mass spectra
(MS) were obtained with a Hitachi M-80B mass spectrometer
using an electronic ionization method, unless mentioned other-
wise. Secondary ion mass spectra (SIMS) were obtained with a
Hitachi M-80A mass spectrometer. FAB-MS were measured on a
JEOL JMS-HX110 double-focusing mass spectrometer. Optical
rotation was measured on a Horiba SEPA-200 polarimeter. In
general, reactions carried out under anhydrous conditions utilized
in dry solvents under argon atmosphere.
4.4. 3,3P-Docosamethylenedioxycarbonyl-bis[5(R)-
hydroxymethytetronic acid] (7)
To a solution of 14 (200 mg, 0.384 mmol) in THF (3.0 ml) were
added 1,22-docosanediol (32.8 mg, 0.0957 mmol) and silver tri-
£uoroacetate (213 mg, 0.962 mmol), and the mixture was stirred
at 23‡C for 3 h while shielded from light. The mixture was diluted
with ether, passed through a short silica gel column, and concen-
trated. The residue was puri¢ed by silica gel column chromatog-
raphy (hexane-AcOEt, 10:1^5:1) to give 1,22-bis{3-[1(R)-meth-
oxycarbonyl-2-triphenylmethyloxyethyl]oxy-3-oxopropanoyloxy}-
docosane (72.7 mg, 63%) as a colorless oil.
1H-NMR (CDCl3, 500 MHz) N 1.27 (m, 36H), 1.61 (m, 4H),
3.49 (d, J = 4.1 Hz, 4H), 3.52 (d, J = 16.3 Hz, 2H), 3.54 (d, J = 16.3
Hz, 2H), 3.73 (s, 6H), 4.13 (t, J = 7.1 Hz, 4H), 5.27 (t, J = 4.1 Hz,
2H), 7.20^7.35 (m, 18H), 7.41 (d, J = 7.5 Hz, 12H); IR (neat)
2920, 2850, 1755, 1735, 1445, 1210, 705 cm31 ; SIMS m/z 1225
(M+Na).
To a solution of 1,22-bis{3-[1(R)-methoxycarbonyl-2-triphenyl-
methyloxyethyl]oxy-3-oxopropanoyloxy}docosane (72.7 mg,
0.0604 mmol) in THF (0.9 ml) was added TBAF (1 M THF
solution, 0.18 ml, 0.18 mmol), and the mixture was stirred at
23‡C for 3 h. After the second addition of TBAF (0.18 ml,
0.18 mmol), the mixture was further stirred for 16.5 h at 23‡C.
Fig. 6. E¡ects of compounds 8 and 13 on VHR-catalyzed hydrolysis of
pNPP. (A) Concentration-dependent inhibition of VHR by compounds
1 (a), 8 (E), and 13 (F). (B) Lineweaver^Burk plot of the e¡ect of 8 on
VHR activity. Concentrations of 8 were 0 (a), 1.25 (b), 2.5 (E), and
5.0 (F) WM, respectively. (C) Second-order plot of (B).
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The reaction mixture was quenched by the addition of 1 N aque-
ous HCl and poured into ice-water; the mixture was then ex-
tracted with CHCl3. The organic layer was washed with brine,
dried (Na2SO4), and concentrated. The residue was puri¢ed by
silica gel column chromatography (CHCl3^MeOH, 20:1^10:1) to
give crude 3,3P-docosamethylenedioxycarbonyl-bis[5(R)-triphenyl-
methyloxymethytetronic acid] as a yellow solid. This material was
dissolved in a mixture of methanol (4.0 ml) and CHCl3 (1.0 ml),
and 1 N aqueous HCl (0.12 ml, 0.12 mmol) was added to the
solution. The mixture was stirred at 23‡C for 16.5 h. After re-
moval of the solvent in vacuo, the residue was puri¢ed by silica
gel column chromatography (CHCl3^MeOH, 1:0^3:1). The com-
bined and concentrated fractions containing the desired product
were redissolved in CHCl3, washed with 0.5 N aqueous HCl and
water, dried (Na2SO4), and concentrated to give 7 (16.0 mg, 40%)
as a colorless solid.
1H-NMR (DMSO-d6, 500 MHz) N 1.27 (m, 36H), 1.54 (m,
4H), 3.57 (dd, J = 12, 4.3 Hz, 2H), 3.71 (dd, J = 12, 2.4 Hz,
2H), 3.99 (t, J = 6.5 Hz, 4H), 4.66 (m, 2H); IR (KBr) 3420,
2920, 2850, 1715, 1600, 1455, 1055 cm31 ; FABMS (+NaCl) m/z
655 (M+H), 677 (M+Na); HR-FABMS (+NaCl) (M-
2H+3Na) calculated for C34H52O12Na3 : 721.3152, found
721.3105; mp 140‡C (dec.).
4.5. Methyl 3-oxo-tridecanoate (9)
To a solution of undecanoic acid (2.79 g, 15.0 mmol) in THF
(180 ml) was added N,NP-carbonyldiimidazole (CDI) (4.86 g, 30.0
mmol), and the mixture was stirred at 23‡C for 3 h. To this
mixture malonic acid monomethyl ester magnesium salt (9.10 g,
30.0 mmol) was added, and the mixture was stirred at 23‡C for 20
h. After further addition of the magnesium salt (910 mg, 3.00
mmol) and stirring at 23‡C for 23 h, the reaction was quenched
by the addition of saturated aqueous NH4Cl, and the mixture
was then extracted with AcOEt. The organic layer was washed
with saturated aqueous NH4Cl and brine, dried (Na2SO4), and
concentrated. The residue was puri¢ed by silica gel column chro-
matography (hexane-AcOEt, 50:1^20:1) to give 9 (3.46 g, 95%)
as a colorless oil.
1H-NMR (CDCl3, 200 MHz) N 0.88 (t, J = 6.9 Hz, 3H), 1.26
(m, 14H), 1.58 (m, 2H), 2.19 (t, J = 7.6 Hz, 2/6H), 2.53 (t, J = 7.4
Hz, 10/6H), 3.45 (s, 10/6H), 3.73 (s, 3/6H), 3.74 (s, 15/6H), 4.99
(s, 1/6H), 12.02 (s, 1/6H); 13C-NMR (CDCl3, 125 MHz) N 14.05,
22.63, 23.45, 28.97, 29.25, 29.31, 29.40, 29.50, 31.84, 43.04, 48.98,
52.25, 167.65, 202.77; IR (neat) 2930, 2860, 1755, 1720, 1240
cm31. MS m/z 242 (M), 169, 129, 116 (bp); Anal. Calculated
for C14H26O3 : C, 69.38; H, 10.81. Found: C, 68.38; H, 10.60.
4.6. Methyl (S)-3-hydroxytridecanoate (10)
To a degassed solution of 9 (576.8 mg, 2.38 mmol) in methanol
(0.8 ml) were added 2 N aqueous HCl (1.5 Wl, 0.1 mol%) and
dichloro[(S)-(3)-2,2P-bis(diphenylphosphino)-1,1P-binaphthyl]ru-
thenium (II) dimer triethylamine adduct (1.9 mg, 0.05 mol%).
After degassing by ¢ve freeze^pump^thaw cycles the mixture
was transferred to an autoclave, and stirred at 60‡C under hydro-
gen (5 atm) for 20 h. After addition of hexane, the resulting
precipitate was removed by ¢ltration, and the ¢ltrate was con-
centrated. The residue was puri¢ed by silica gel column chroma-
tography (hexane-AcOEt, 10:1) to give 10 (553.3 mg, 96%, 97%
ee) as a colorless solid.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 7.0 Hz, 3H),
1.26 (m, 15H), 1.43 (m, 2H), 1.52 (m, 1H), 2.41 (dd, J = 9.0,
16.4 Hz, 1H), 2.51 (dd, J = 3.4, 16.4 Hz, 1H), 2.81 (d, J = 4.1
Hz, 1H), 3.71 (s, 3H), 4.00 (m, 1H); 13C-NMR (CDCl3, 125
MHz) N 14.06, 22.64, 25.45, 29.29, 29.49, 29.52, 29.55, 29.57,
31.87, 36.54, 41.12, 51.66, 68.01, 173.44; IR (neat) 3540, 2920,
2850, 1720, 1205, 1180 cm31 ; MS m/z 244 (M), 226 (M-H2O),
103 (bp); CIMS (isobutane): 245 (M+H), 227 (M-OH);
HRMS (M) calculated for C14H28O3 : 244.2037. Found
244.2037.
[K]20D +15.12‡ (c 0.655, CHCl3); mp 37‡C.
The ee of the product was determined by the NMR analysis (in
CDCl3) of its K-methoxy-K-tri£uoromethylphenylacetyl (MTPA)
ester. Brie£y, 10 was treated with (S)-(+)-MTPA chloride (1.5 eq)
and pyridine (10 eq) in CH2Cl2 at 0‡C for 17 h to give the MTPA
ester in 98% yield. The racemic 10 prepared by the reduction of
9 with sodium borohydride was similarly converted to its MTPA
ester using (S)-MTPA chloride. Enantiomeric excess was deter-
mined from the integration values of singlets at 3.59 ppm and
3.66 ppm due to the ester methyl group of the (S)- and (R)-
isomer, respectively.
4.7. Methyl (S)-3-allyloxytridecanoate
To a stirred solution of tris(dibenzylideneacetone)dipalladium
complex (Pd2(dba)3bCHCl3), (127.8 mg, 0.123 mmol) and 1,4-
bis(diphenylphosphino)butane (dppb) (210.1 mg, 0.493 mmol)
in degassed THF were added 10 (1.20 g, 4.91 mmol) and allyl
ethyl carbonate (2.60 ml, 19.8 mmol), and the mixture was stirred
at 60V65‡C for 9 h with bubbling of argon to remove CO2.
After removal of the solvent, the residue was puri¢ed by silica
gel column chromatography (hexane-AcOEt, 50:1^20:1) to give
methyl (S)-3-allyloxytridecanoate (916.8 mg, 66%) as a pale yel-
low oil.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 3H), 1.33
(m, 16H), 1.53 (m, 2H), 2.44 (dd, J = 5.4, 15.1 Hz, 1H), 2.56 (dd,
J = 7.3, 15.1 Hz, 1H), 3.68 (s, 3H), 3.78 (m, 1H), 4.01 (d, J = 5.6
Hz, 2H), 5.14 (dd, J = 1.6, 10.4 Hz, 1H), 5.25 (dd, 1.6, 17.2 Hz,
1H), 5.89 (tdd, J = 5.6, 10.4, 17.2 Hz, 1H); 13C-NMR (CDCl3,
125 MHz) N 14.07, 22.65, 25.15, 29.30, 29.53, 29.56, 29.58, 29.61,
31.88, 34.44, 39.77, 51.53, 70.45, 75.89, 116.61, 135.09, 172.24; IR
(neat) 2940, 2860, 1745, 1440, 1090, 925 cm31 ; MS m/z 253 (M-
OMe), 243 (M-CH2CH = CH2), 228, 169, 143, 101, 41 (bp);
CIMS (isobutane): 285 (M+H); HRMS (M+H) calculated
for C17H33O3 : 285.2428. Found 285.2448.
[K]20D +6.48‡ (c 1.11, CHCl3).
4.8. Methyl (S)-3-(2-hydroxyethyl)oxytridecanoate
Ozone was introduced into a stirred solution of methyl (S)-3-
allyloxytridecanoate (916 mg, 3.22 mmol) in methanol (100 ml) at
360V350‡C for 75 min. After bubbling of argon, dimethylsul-
¢de (2.0 ml, 27.2 mmol) was added at the same temperature, and
the mixture was warmed to 23‡C over 3 h. Stirring was continued
for an additional 1 h at the same temperature, then the solvent
was removed. The residue was dissolved in methanol (12.0 ml),
and sodium borohydride (125.6 mg, 3.32 mmol) was added at
0‡C. More sodium borohydride (61.4 mg, 63.1 mg, and 125.6
mg, respectively) was added after stirring at 0‡C for 0.5, 1 and
1.5 h. After addition of water the pH of the reaction mixture was
adjusted to 5 with 1 N aqueous HCl, and the solution was ex-
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tracted with CHCl3. The organic layer was washed with brine,
dried (Na2SO4), and concentrated. The residue was puri¢ed by
silica gel column chromatography (hexane-AcOEt, 5:1^3:1) to
give methyl (S)-3-(2-hydroxyethyl)oxytridecanoate (862 mg,
93%) as a colorless oil.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 3H), 1.29
(m, 16H), 1.53 (m, 2H), 2.48 (dd, J = 4.7, 15.6 Hz, 1H), 2.53 (dd,
J = 7.9, 15.6 Hz, 1H), 2.59 (bs, 1H), 3.55 (m, 1H), 3.63^3.70 (m,
3H), 3.70 (s, 3H), 3.81 (m, 1H); 13C-NMR (CDCl3, 125 MHz)
N 14.10, 22.69, 25.14, 29.33, 29.57, 29.59, 29.61, 29.68, 31.92,
34.10, 39.42, 51.76, 62.08, 70.55, 76.44, 172.23; IR (neat) 3475,
2930, 2860, 1740, 1440, 1115, 1060 cm31 ; MS m/z 257 (M-
OMe), 243 (M-CH2CH2OH), 228, 169, 147, 73 (bp); CIMS
(isobutane): 289 (M+H); HRMS (M-OMe) calculated for
C15H29O3 : 257.2115. Found 257.2117.
[K]20D +18.18‡ (c 0.495, CHCl3).
4.9. (S)-3-(2-Hydroxyethyl)oxytridecanoic acid
To a solution of methyl (S)-3-(2-hydroxyethyl)oxytridecanoate
(751.1 mg, 2.48 mmol) in methanol (14 ml) was added 1 N aque-
ous NaOH (7.0 ml, 7.0 mmol) at 0‡C, and the mixture was stirred
at 23‡C for 3 h. The reaction mixture was acidi¢ed to pH 3 with
1 N aqueous HCl, followed by extraction with CH2Cl2. The
combined organic layers were washed with water and brine, dried
(Na2SO4), and concentrated to a¡ord (S)-3-(2-hydroxyethyl)oxy-
tridecanoic acid (667.3 mg, 98%) as a colorless solid.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 3H), 1.26
(m, 16H), 1.50 (m, 1H), 1.62 (m, 1H), 2.52 (dd, J = 7.6, 15.8 Hz,
1H), 2.56 (dd, J = 4.8, 15.8 Hz, 1H), 3.08 (broad), 3.56 (m, 1H),
3.68^3.75 (m, 3H), 3.80 (m, 1H); 13C-NMR (CDCl3, 125 MHz)
N 14.07, 22.65, 25.09, 29.29, 29.52, 29.55, 29.57, 29.62, 31.87,
33.92, 39.29, 61.84, 70.43, 76.52, 176.27; IR (neat) 3400, 2930,
2860, 1720, 1465, 1110, 1060 cm31 ; MS m/z 257 (M-OH), 243
(M-CH2OH), 229 (M-CH2CH2OH), 213, 169, 133, 115, 86, 73
(bp); CIMS (isobutane): 275 (M+H); HRMS (M-OH) calcu-
lated for C15H29O3 : 257.2115. Found 257.2129.
[K]20D +16.76‡ (c 0.525, CHCl3); mp 33^34‡C.
4.10. tert-Butyldiphenylsilyl (S)-3-(2-tert-
butyldiphenylsilyloxyethyl)oxytridecanoate
To a solution of (S)-3-(2-hydroxyethyl)oxytridecanoic Acid
(687.4 mg, 2.51 mmol) and imidazole (682.3 mg, 10.1 mmol) in
DMF (3.5 ml) was added tert-butyldiphenylsilyl chloride (1.83
ml, 7.04 mmol) at 0‡C, and the mixture was stirred at 23‡C for
2 h. After addition of water the mixture was extracted with Et2O.
The organic layer was washed with water, dried (Na2SO4), and
concentrated. The residue was puri¢ed by silica gel column chro-
matography (hexane-AcOEt, 30:1) to give tert-butyldiphenylsilyl
(S)-3-(2-tert-butyldiphenylsilyloxyethyl)oxytridecanoate (1.737 g,
92%) as a colorless oil.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 7.0 Hz, 3H), 1.04
(s, 9H), 1.08 (s, 9H), 1.25 (m, 16H), 1.39 (m, 1H), 1.51 (m, 1H),
2.55 (dd, J = 5.8, 15.5 Hz, 1H), 2.71 (dd, J = 6.9, 15.5 Hz, 1H),
3.56 (t, J = 5.2 Hz, 2H), 3.69^3.81 (m, 3H), 7.36 (m, 12H), 7.67
(m, 8H); 13C-NMR (CDCl3, 125 MHz) N 14.12, 19.10, 19.19,
22.69, 25.22, 26.83, 26.93, 29.34, 29.61, 29.63, 29.65, 29.78,
31.93, 34.42, 41.60, 63.46, 70.51, 76.75, 127.61, 127.63, 127.64,
127.66, 129.56, 130.00, 131.86, 131.89, 133.77, 133.82, 135.32,
135.33, 135.62, 135.64, 171.09; IR (neat) 2930, 2860, 1730,
1430, 1115, 700, 505 cm31 ; MS m/z 693 (M-tBu), 481, 425,
393 (bp), 373, 213, 199, 135; CIMS (isobutane): 751 (M+H);
Anal. calculated for C47H66O4Si2 : C 75.15, H 8.86. Found C
74.87, H 8.89.
[K]20D +1.04‡ (c 0.960, CHCl3).
4.11. (S)-3-(2-tert-Butyldiphenylsilyloxyethyl)oxytridecanoic
acid (11)
To a solution of tert-butyldiphenylsilyl (S)-3-(2-tert-butyldi-
phenylsilyloxyethyl)oxytridecanoate (1.682 g, 2.24 mmol) in
THF (22.4 ml) were added methanol (33.5 ml) and an aqueous
solution of K2CO3 (929.0 mg, 6.72 mmol in 11.2 ml), and the
mixture was stirred at 23‡C for 1 h. After removal of organic
solvent by evaporation brine was added, and the mixture was
acidi¢ed to pH 2^3 with 1 M KHSO4, followed by extraction
with Et2O. The organic layer was washed with brine, dried
(Na2SO4), and concentrated. The residue was puri¢ed by silica
gel column chromatography (CHCl3^MeOH, 100:1) to give 11
(1.068 g, 93%) as a colorless oil.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 3H), 1.05 (s,
9H), 1.25 (m, 16H), 1.52 (m, 1H), 1.63 (m, 1H), 2.54 (dd, J = 6.9,
15.8 Hz, 1H), 2.61 (dd, J = 4.4, 15.8 Hz, 1H), 3.60 (m, 1H), 3.65
(m, 1H), 3.74 (m, 2H), 3.81 (m, 1H), 7.41 (m, 6H), 7.67 (m, 4H),
9.65, (bs, 1H); 13C-NMR (CDCl3, 125 MHz) N 14.09, 19.11,
22.66, 25.00, 26.77, 29.30, 29.53, 29.57, 29.58, 29.62, 31.89,
33.93, 39.07, 63.28, 70.53, 76.34, 127.65, 129.65, 133.48, 135.61,
175.32; IR (neat) 2930, 2860, 1710, 1430, 1110, 705, 505 cm31 ;
MS m/z 495 (M-OH), 455 (M-tBu), 437, 377, 299, 243, 199,
165 (bp); HRMS (M-OH) calculated for C31H47O3Si: 495.3291.
Found 495.3262.
[K]20D +5.74‡ (c 0.940, CHCl3).
4.12. (R)-5-[(S)-3-(2-tert-Butyldiphenylsilyloxyethyl)-
oxytridecanoyl]oxymethyl-4-hydroxy-3-hexadecanoylfuran-
2-(5H)-one (12)
To a solution of 11 (324 mg, 0.632 mmol) in CH2Cl2 (2.2 ml)
were added DMF (2 drops) and oxalyl chloride (0.22 ml, 2.52
mmol) at 0‡C, and the mixture was stirred at 23‡C for 16 h. After
evaporation of the volatile materials, the residue was redissolved
in CH2Cl2. To this solution was added a solution of 1 (465.8 mg,
1.264 mmol) in CH2Cl2 (22.0 ml), and then pyridine (80.92 ml,
11.37 mmol) was added at 0‡C. The mixture was stirred at 23‡C
for 48 h, and quenched by the addition of saturated aqueous
NaHCO3. The mixture was acidi¢ed to pH 4 with 0.5 N aqueous
HCl, followed by extraction with CH2Cl2. The organic layer was
dried (Na2SO4), and concentrated. The residue was puri¢ed by
silica gel column chromatography (hexane-AcOEt, 1:0^0:1, and
then CHCl3^MeOH, 5:1^3:1) to give 12 (485.1 mg, 89%) as a
pale yellow oil, and 1 (69.6 mg) was recovered from the fraction
eluted with CHCl3^MeOH.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 6H), 1.04
(s, 9H), 1.25 (m, 40H), 1.49 (m, 2H), 1.69 (m, 2H), 2.40 (m, 1H),
2.61 (m, 1H), 2.9 (m, 2H), 3.54 (m, 2H), 3.69 (m, 1H), 3.74
(m, 2H), 4.30 (m, 1H), 4.56 (dd, J = 3.0, 12.4 Hz, 1H), 4.76
(dd, J = 2.8, 4.6 Hz, 0.5H), 4.87 (dd, J = 3.2, 4.4Hz, 0.5H), 7.39
(m, 6H), 7.68 (m, 4H); IR (neat) 3460, 2920, 2850, 1745, 1695,
1600, 1460, 1110, 700 cm31 ; MS m/z 693, 373, 350, 299, 243, 199
(bp), 165; CIMS (isobutane): 861 (M+H), 805 (M-tBu), 785
(M-Ph); HR-FABMS (glycerol :nitrobenzylalcohol = 1:2,
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+NaCl) (M+Na) calculated for C52H82O8SiNa: 885.5677.
Found 885.5687.
4.13. (R)-5-[(S)-3-(2-Hydroxyethyl)oxytridecanoyl]oxymethyl-
4-hydroxy-3-hexadecanoylfuran-2-(5H)-one (13)
To a solution of 12 (342.5 mg, 0.397 mmol) in THF (10.0 ml)
was added TBAF (1 M THF solution, 0.67 ml, 0.67 mmol), and
the mixture was stirred at 23‡C for 5 h. The reaction mixture was
quenched by the addition of saturated aqueous NH4Cl and then
extracted with Et2O. The organic layer was washed with brine,
dried (Na2SO4), and concentrated. The residue was puri¢ed by
silica gel thin layer chromatography (CHCl3^MeOH, 10:1) and
following 0.5 N aqueous HCl treatment to give 13 (180.2 mg,
73%) as a pale yellow amorphous solid.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 6H), 1.26
(m, 38H), 1.41 (m, 3H), 1.56 (m, 1H), 1.71 (m, 2H), 2.47
(d, J = 5.2 Hz, 2H), 2.93 (br t, J = 7.4 Hz, 2H), 3.51 (m, 1H),
3.62 (m, 1H), 3.67 (m, 2H), 3.74 (m, 1H), 4.42 (m, 1H), 4.58
(m, 1H), 4.81 (br s, 0.5H), 4.92 (br s, 0.5H); 13C-NMR (CDCl3,
125 MHz) N 14.12, 22.69, 22.70, 25.15, 29.24, 29.34, 29.37, 29.43,
29.59, 29.60, 29.62, 29.67, 29.69, 29.71, 29.72, 31.92, 31.94, 33.97,
39.31, 61.82, 62.04, 70.57, 76.29, 77.25, 171.38 (carbonyl car-
bons of the tetronic acid group were not observed in CDCl3
due to tautomeric isomerization); IR (neat) 3500, 2910,
2840, 1740, 1690, 1600, 1460 cm31 ; MS m/z 606 (M-H2O),
350, 154, 115, 86 (bp), 73; CIMS (isobutane): 625 (M+H),
607 (M-OH); HR-FABMS (glycerol :nitrobenzylalcohol = 1:2,
+NaCl) (M+ Na) calculated for C36H64O8Na: 647.4499. Found
647.4476.
[K]20D +39.79‡ (c 0.960, CHCl3).
4.14. (R)-5-[(3S,12R)-3-Decyl-12-methoxycarbonyl-4,7,11-
trioxa-8,10-dioxo-13-(triphenylmethyoxy)tetradecanoyl]
oxymethyl-3-hexadecanoyl-4-hydroxyfuran-2-(5H)-one (15)
To a solution of 13 (71.3 mg, 0.0676 mmol) and 14 (127.7 mg,
0.245 mmol) in benzene (60.0 ml) were added Na2HPO4 (208.7
mg, 1.470 mmol) and silver tri£uoroacetate (170.3 mg, 0.771
mmol), and the mixture was stirred at 23‡C for 5 h while shielded
from light. Then it was re£uxed for 30 min without shielding
from light. The resulting black insoluble material was removed
by ¢ltration through a Celite pad, and the ¢ltrate was concen-
trated. The residue was puri¢ed by silica gel column chromatog-
raphy (CHCl3^MeOH, 15:1) followed by 0.5 N aqueous HCl
treatment to give 15 (98.1 mg, 60%) as a colorless oil. A mixture
fraction containing 16 (64 mg) was also obtained.
1H-NMR (CDCl3, 500 MHz) N 0.88 (m, 6H), 1.25 (m, 38H),
1.38 (m, 3H), 1.50 (m, 1H), 1.69 (m, 2H), 2.44 (m, 2H), 2.91
(m, 2H), 3.50 (d, J = 4.1 Hz, 2H), 3.58 (s, 2H), 3.65 (m, 3H),
3.73 (s, 3H), 4.23 (m, 2H), 4.35 (m, 1H), 4.58 (m, 1H), 4.78
(dd, J = 2.8, 4.6 Hz, 0.5H), 4.88 (dd, J = 3.2, 4.2 Hz, 0.5H), 5.27
(m, 1H), 7.24 (m, 3H), 7.30 (t, J = 7.5 Hz, 6H), 7.41 (d, J = 7.5
Hz, 6H); IR (neat) 3480, 2920, 2850, 1740, 1695, 1600, 1450,
1095, 705 cm31 ; FABMS (glycerol :nitrobenzylalcohol = 1:2,
+NaCl) m/z 1099 (M-H+2Na), 1077 (M+Na), 857, 835, 243
(bp); HR-FABMS (glycerol :nitrobenzylalcohol = 1:2, +NaCl)
(M+Na) calculated for C62H86O14Na: 1077.5915. Found
1077.5924.
4.15. (R)-5-{3(S)-Decyl-6-[2,5-dihydro-4-hydroxy-5(R)-
hydroxymethyl-2-oxofuran-3-yl]carbonyloxy-4-oxahexanoyl}
oxymethyl-3-hexadecanoyl-4-hydroxyfuran-2-(5H)-one (8)
To a solution of 15 (71.3 mg, 0.0676 mmol) in THF (1.2 ml)
was added TBAF (1 M THF solution, 0.14 ml, 0.14 mmol), and
the mixture was stirred at 23‡C for 31 h. During the reaction
TBAF (0.14 ml after 17 h, and 0.07 ml after 25 h) was further
added to complete the reaction. The reaction mixture was acidi-
¢ed to pH 3 with 0.5 N aqueous HCl and poured into ice-water;
the mixture was then extracted with Et2O. The combined organic
layers were washed with brine, dried (Na2SO4), and concentrated.
The residue was puri¢ed by silica gel column chromatography
(CHCl3^MeOH, 10:1) and following 0.5 N aqueous HCl treat-
ment to give (R)-5-{3(S)-decyl-6-[2,5-dihydro-4-hydroxy-2-oxo-
5(R)-(triphenylmethyloxymethyl)furan-3-yl]carbonyloxy-4-oxa-
hexanoyl}oxymethyl-3-hexadecanoyl-4-hydroxyfuran-2-(5H)-one
(38.5 mg, 73%) as a pale yellow oil.
1H-NMR (CDCl3, 500 MHz) N 0.88 (m, 6H), 1.25 (m, 38H),
1.39 (m, 3H), 1.55 (m, 1H), 1.66 (m, 2H), 2.47 (m, 2H), 2.91
(m, 2H), 3.41 (dd, J = 4.1, 10.5 Hz, 1H), 3.66 (dd, J = 3.0, 10.5
Hz, 1H), 3.78 (m, 3H), 4.38 (m, 2H), 4.48 (m, 1H), 4.77 (br s,
0.5H), 4.87 (br s, 0.5H), 4.93 (br s, 1H), 7.20^7.33 (m, 9H), 7.39
(d, J = 7.5 Hz, 6H); IR (neat) 2920, 2850, 1770, 1740, 1695, 1640,
1600, 1465, 1060, 705 cm31 ; FABMS (glycerol :nitrobenzylalco-
hol = 1:2, +NaCl) m/z 1089 (M-2H+3Na), 669, 647, 243 (bp);
HR-FABMS (glycerol :nitrobenzylalcohol = 1:2, +NaCl) (M-
2H+3Na) calculated for C61H80O13Na3 : 1089.5292. Found
1089.5255.
To a solution of (R)-5-{3(S)-decyl-6-[2,5-dihydro-4-hydroxy-2-
oxo-5(R)-(triphenylmethyloxymethyl)furan -3-yl]carbonyloxy-4-
oxahexanoyl}oxymethyl-3-hexadecanoyl-4-hydroxyfuran-2-(5H)-
one (51.6 mg, 0.0504 mmol) in methanol (1.5 ml) was added 1 N
aqueous HCl (0.10 ml, 0.10 mmol), and the mixture was stirred at
23‡C for 6 h. After removal of the solvent in vacuo, the residue
was puri¢ed by silica gel thin layer chromatography (CHCl3^
MeOH, 5:1) and following 0.5 N aqueous HCl treatment to
give 8 (32.2 mg, 82%) as a colorless amorphous solid.
1H-NMR (CDCl3, 500 MHz) N 0.88 (t, J = 6.9 Hz, 6H), 1.29
(m, 38H), 1.41 (m, 3H), 1.55 (m, 1H), 1.70 (m, 2H), 2.45
(dd, J = 4.5, 15.7 Hz, 1H), 2.50 (dd, J = 7.8, 15.7 Hz, 1H), 2.92
(m, 2H), 3.77 (m, 3H), 3.98 (dd, J = 3.2, 12.5 Hz, 1H), 4.13
(dd, J = 2.3, 12.5 Hz, 1H), 4.38 (m, 2H), 4.48 (m, 1H), 4.58
(dd, J = 2.8, 12.5 Hz, 1H), 4.89 (br s, 1H), 4.94 (br s, 1H);
13C-NMR (CD3OD, 125 MHz) N 14.48, 14.50, 23.76, 23.78,
26.30, 30.50, 30.53, 30.65, 30.80, 30.82, 30.83, 33.13, 35.31,
40.44, 61.31, 63.10, 64.65, 68.35, 78.14, 80.47, 80.88, 95.31,
100.22, 163.58, 172.09, 172.32, 173.51, 188.11, 194.72, 195.92;
IR (neat) 3450, 2920, 2850, 1770, 1740, 1690, 1650, 1465, 1050
cm31 ; FABMS (glycerol :nitrobenzylalcohol = 1:1, +NaCl) m/z
825 (M-H+2Na), 803 (M+Na), 781 (M+H), 669, 647, 242
(bp); HR-FABMS (glycerol:nitrobenzylalcohol = 1:2, +NaCl)
(M+Na) calculated for C42H68O13Na: 803.4558. Found
803.4550.
[K]20D +40.41‡ (c 0.480, CHCl3).
Crude mixture containing 16 was also converted to 8 as fol-
lows. To a solution of 16 (37.3 mg, maximum 0.0356 mmol) in
THF (0.8 ml) was added TBAF (1 M THF solution, 0.095 ml,
0.095 mmol), and the mixture was stirred at 23‡C for 22 h. Dur-
ing the reaction TBAF (0.19 ml) was further added after 6 h to
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complete the reaction. The reaction mixture was acidi¢ed to pH 3
with 0.5 N aqueous HCl and poured into ice-water; the mixture
was then extracted with Et2O and Et2O-methanol = 1:1. The
combined organic layers was washed with brine, dried (Na2SO4),
and concentrated. The residue was puri¢ed by silica gel thin layer
chromatography (CHCl3^MeOH, 5:1) and following 0.5 N aque-
ous HCl treatment to give 8 (19.1 mg, 69%V) as a pale yellow
oil.
4.16. Binding model of VHR-(RK-682)2 complex
The 3D structure of the complex of VHR and two RK-682
molecules was estimated through energy minimization and dy-
namics simulation. The initial structure was generated by docking
two RK-682 molecules to a VHR molecule manually, considering
the putative binding site and the interaction energy in a vacuum,
using the computer program Hyper-Chem (Hypercube Inc., Can-
ada). The 3D structure of the VHR molecule based on X-ray
crystallography has already been reported [5] and was used in
the present study as the initial structure. For energy minimization
and analysis of the molecular dynamics in water, we used the
Amber 4.1 computer package (Pearlman, DA, Case DA, Cald-
wall JW, Amber 4.1 1995; UCSF, San Francisco, CA) and a
Spark Station 5 workstation (Sun Inc., USA) with a specially
designed board, the MD-engine (Fuji-Xerox, Japan), for molec-
ular dynamics calculation. The initial structure of the complex
was solvated with 3711 TIP3P water molecules, using a protein
box size of 5.9U5.0U4.1 nm3. The minimum thickness of the
solvent shell was 0.6 nm. We basically followed the Ewald meth-
od to treat the electrostatics, using a 0.6 nm cuto¡, a 1 fs time
step and constant volume with periodic boundary conditions. The
non-bonded pair list was updated every 20 steps. The energy of
the solvated structure was minimized with 100 steps. The molec-
ular dynamics simulation was done from the energy-minimized
structure. At ¢rst, the temperature in the simulation was in-
creased rapidly from 0 K to 400 K in 10 K steps with a 0.1 ps
calculation for each of the steps. The temperature of the system
was controlled by Berendsen’s algorithm with a 0.2 ps coupling
constant. After the scanning, a constant temperature simulation
was done at 310 K for 10 ps. Finally the temperature of the
system was decreased slowly from 310 K to 0 K in 1 K steps,
with a 0.1 ps simulation for each step. The total energy of the
¢nal structure was substantially lower than that of the energy-
minimized structure.
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